

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1






Complete if Known

Application Number	10/556,228
Filing Date	November 9, 2005
First Named Inventor	Martin Hemmerling, et. al.
Art Unit	Not Known 1625
Examiner Name	Not Known Corry
Attorney Docket Number	101056-1P US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Y ^a
		Country Code** Number*** Kind Code† (if known)				
	A3	WO 02/092571 A1	11-21-2002	Joakim Larsson, et. al.		
	A4	WO 00/18761	04-06-2000	Allan Wissner, et. al.		
	A5	WO 99/65909	12-23-1999	Todd Blumenkopf, et. al.		
	A6	WO 98/43960	10-08-1998	Allan Wissner, et. al.		
						

Examiner
Signature

James C. To

Date
Cons:

Considered

6/1/100

*EXAMINER. Include reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Indicate copy of this form with nearest communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds of Codes and USPTO Patent Documents at www.uspto.gov and MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and) by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the burden of this requirement to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/556,228
Filing Date	November 9, 2005
First Named Inventor	Martin Hemmerling, et. al.
Art Unit	Not Known 1625
Examiner Name	Not Known Conigto
Attorney Docket Number	101056-1P US

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>R</i>	A7	Sauro Vittori, et. al., "N-Cycloalkyl Derivatives of Adenosine . . . Adenosine Receptor", J. Med. Chem., Vol. 43, 2000, pages 250-260, tables 3, 5	
<i>b</i>	A8	Sauro Vittori, et. al., "Deaza- and Deoxyadenosine Derivatives . . . Infection Models", Nucleosides, Nucleotides & Nucleic Acids, Vol. 22, Nos. 5-8, pages, 877-881, 2003	
<i>b</i>	A9	Gloria Cristalli, et. al., "Adenosine Deaminase Inhibitors . . . Adenine Analogues", Drug Development Research 28, pages 253-258, 1993, Figures 1-3	
<i>b</i>	A10	Elise A. Sudbeck, et. al., "Structure-Based Design . . . Antileukemic Agents", Vol. 5, pages 1569-1582, 1999	
<i>h</i>	A11	Diane H. Boschelli, et. al., "Synthesis and Src Kinase Inhibitory . . . 3-Quinolincarbonitriles", J. Med. Chem. 2001, 44, pages 822-833	

Examiner Signature	<i>Raymond Conigto</i>	Date Considered	6/16/08
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.